-- 江蘇恒瑞医薬（上海証券取引所：600276）傘下の山東盛地医薬は、中国国家薬品監督管理局からHRS-7156錠の臨床試験承認を取得した。これは木曜日に上海証券取引所に提出された書類で明らかになった。 この薬剤は心不全治療薬として試験される予定だ。
Related Articles
Asia
Origin Energy Reports Lower March Quarter Production
Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.
$ASX:ORG
Asia
New Hope Says JPMorgan Chase Ceases to be a Substantial Shareholder
New Hope (ASX:NHC) received notice that JPMorgan Chase and its affiliates are no longer substantial holders of the company from April 22, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates became a substantial holder of the company on April 15, with a total voting power of 5.88%, an earlier filing showed.
$ASX:NHC
Asia
Zip Says JPMorgan Chase Increases Stake
Zip (ASX:ZIP) received notice that JPMorgan Chase and its affiliates increased their holdings in the company to 7.42% from 6.27%, according to a Monday Australian bourse filing.JPMorgan Chase and its affiliates now own 93.2 million shares in the company, the filing said.
$ASX:ZIP